Donor immune cells take on Hard-to-Treat cancers in early trial

NCT ID NCT05239143

Ongoing Disease control Sponsor: Poseida Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and attack cancer cells. The main goals are to find a safe dose and see if the treatment can shrink tumors. About 180 adults are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: P-MUC1C-ALLO1 CAR-T cells (a type of immune cell therapy made from donor cells, designed to attack cancer cells that have a protein called MUC1-C)
What this could lead to: If this works, it could point toward a new treatment option for several hard-to-treat cancers that have spread or come back.
What could go wrong: This is a very early (Phase 1) trial with only 180 people, so it is mainly checking safety and dosing. The therapy may not shrink tumors, and there could be serious side effects like cytokine release syndrome or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm gastric cancer gastric neoplasm head and neck squamous cell carcinoma malignant pancreatic neoplasm nasopharyngeal carcinoma, susceptibility to, 1 nasopharyngeal neoplasm non-small cell lung carcinoma ovarian cancer pancreatic neoplasm renal cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER COLORECTAL CANCER GASTRIC CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA NASOPHARYNGEAL CANCER NON-SMALL CELL LUNG CANCER OVARIAN CANCER PANCREATIC CANCER RENAL CELL CARCINOMA

Contacts and locations

Locations

Cancer Center of Kansas

Wichita, Kansas, 67214, United States
Cedars Sinai Medical Center

Los Angeles, California, 90048, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE

Denver, Colorado, 80218, United States
University of California, Irvine Medical Center

Irvine, California, 92868, United States
University of California, San Diego

San Diego, California, 92037, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Kansas Cancer Center

Westwood, Kansas, 66205, United States
University of Maryland Cancer Center

Baltimore, Maryland, 21201, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.